Publication | Closed Access

Weekly Docetaxel and Bortezomib as First-Line Treatment for Patients with Hormone-Refractory Prostate Cancer: A Minnie Pearl Cancer Research Network Phase II Trial

UrologyGenitourinary CancerMedicineWeekly DocetaxelFirst-line TreatmentPharmacotherapyCancer TreatmentProstatic DiseaseOncologyRadiation OncologyHormone-refractory Prostate Cancer